EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cisplatin Promotes Immunosuppression in Ovarian Cancer by Enhancing miR‐181a‐5p‐Enriched Extracellular Vesicles to Drive Regulatory T Cell Differentiation

Liyan Zheng, Sijia Mu, Mingxue Liu, Panmin Lei, Jingchen Zhang, Yuting Dai, Chenxi He, Fengli Qu, Weihong Tan

Journal of Extracellular Vesicles · 2026-04 · 15 (4)

DOI: 10.1002/jev2.70261 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Although cisplatin (CDDP) is widely employed in combination immunotherapy, no CDDP‐based regimen has shown a survival benefit when treating the ovarian cancers. This is mainly because the impact of CDDP on immunotherapy is not fully understood. A critical gap concerns how CDDP reshape the tumour microenvironment, especially through extracellular vesicles (EVs)‐mediated communication. In this work, using human and murine ovarian cancer cells as a model, we demonstrate that CDDP boosts the secretion of EVs from cancer cells, while exerting no such effect on non‐cancerous cells. These CDDP‐induced tumour‐derived EVs, in turn, drive the differentiation of CD4 + T cells towards immunosuppressive regulatory T cells (T reg cells), which are known to limit the efficacy of immunotherapy. Based on next‐generation sequencing, a significant enrichment of miR‐181a‐5p was identified in CDDP‐induced tumour‐derived EVs, and further functional studies confirmed that this microRNA promoted T reg cell differentiation via suppressing sirtuin 1 (SIRT1), a key regulator of the transcription factor forkhead box protein P3 (FOXP3). Importantly, inhibition of miR‐181a‐5p abrogated the T reg ‐promoting effect of CDDP‐induced tumour‐derived EVs, a finding further validated in vivo , where blockade of miR‐181a‐5p not only impaired T reg differentiation but also restored T‐cell‐mediated antitumour immunity and restrained tumour growth. Together, these findings uncover a previously unrecognised mechanism by which CDDP exacerbates immunosuppression via miR‐181a‐5p‐enriched EVs and suggest that targeting this pathway could improve the therapeutic efficacy of combination immunotherapy in ovarian cancer.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →